ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022
Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
No numbers read from the abstract.